UNQ6126 Inhibitors
The chemical class referred to as UNQ6126 Inhibitors comprises a diverse group of compounds that act through various mechanisms to potentially inhibit the UNQ6126 protein. These inhibitors target different cellular pathways involved in UNQ6126 activation and function. Retinoic Acid, for instance, modulates gene expression by binding to retinoic acid receptors, potentially suppressing UNQ6126 activation. Trichostatin A, a histone deacetylase inhibitor, affects histone acetylation, leading to transcriptional changes that may suppress UNQ6126 expression.
Geldanamycin, an Hsp90 inhibitor, disrupts chaperone-mediated folding, impacting UNQ6126 stability. TPCA-1 and IWP-2 target the NF-κB and Wnt pathways, respectively, potentially downregulating UNQ6126 expression. Bortezomib prevents proteasomal degradation, affecting UNQ6126 stability. GSK-J4, a JMJD3/UTX inhibitor, may influence UNQ6126 activation through histone demethylation. AG-879 and PP2 target HER2 and Src-dependent pathways, respectively, potentially negatively affecting UNQ6126 activation. SP600125 and PD0325901 inhibit the JNK and MEK/ERK pathways, disrupting downstream events crucial for UNQ6126 functionality.
The diversity in mechanisms showcased by UNQ6126 Inhibitors highlights the intricate regulation of UNQ6126 and the interconnectedness of cellular pathways influencing its activation. Researchers can employ these inhibitors to unravel the complex regulatory networks associated with UNQ6126 and gain insights into avenues for conditions associated with dysregulated UNQ6126 function.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic Acid, a derivative of vitamin A, can inhibit UNQ6126 by modulating gene expression. It binds to retinoic acid receptors, influencing transcriptional regulation and potentially suppressing UNQ6126 activation. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A, an HDAC inhibitor, can hinder UNQ6126 by affecting histone acetylation. This alteration in chromatin structure may lead to transcriptional changes, suppressing UNQ6126 expression and activity. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $39.00 $59.00 $104.00 $206.00 | 8 | |
Geldanamycin, an Hsp90 inhibitor, can inhibit UNQ6126 by disrupting chaperone-mediated folding. This interference may lead to proteasomal degradation or misfolding, negatively impacting UNQ6126 stability and function. | ||||||
IKK-2 Inhibitor IV | 507475-17-4 | sc-203083 | 500 µg | $133.00 | 12 | |
TPCA-1, an IKK-2 inhibitor, can potentially inhibit UNQ6126 by disrupting the NF-κB pathway. Inhibition of IKK-2 prevents the activation of NF-κB, which may downregulate UNQ6126 expression and activity. | ||||||
C646 | 328968-36-1 | sc-364452 sc-364452A | 10 mg 50 mg | $265.00 $944.00 | 5 | |
C646, a histone acetyltransferase (HAT) inhibitor, may inhibit UNQ6126 by modulating histone acetylation. This alteration in chromatin structure can impact transcription, leading to suppressed UNQ6126 activation. | ||||||
Tyrphostin AG 879 | 148741-30-4 | sc-3557 sc-3557A | 5 mg 25 mg | $83.00 $328.00 | 4 | |
AG-879, a HER2 inhibitor, can potentially inhibit UNQ6126 by targeting HER2-mediated signaling pathways. This interference may lead to downstream effects that negatively impact UNQ6126 activation and functionality. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib, a proteasome inhibitor, can hinder UNQ6126 by preventing proteasomal degradation. This leads to the accumulation of misfolded or ubiquitinated UNQ6126, negatively affecting its stability and function. | ||||||
GSK-J4 | 1373423-53-0 | sc-507551 | 100 mg | $1275.00 | ||
GSK-J4, a JMJD3/UTX inhibitor, may inhibit UNQ6126 by affecting histone demethylation. This alteration in epigenetic regulation can influence gene expression, potentially suppressing UNQ6126 activation. | ||||||
IWP-2 | 686770-61-6 | sc-252928 sc-252928A | 5 mg 25 mg | $96.00 $292.00 | 27 | |
IWP-2, a Wnt/β-catenin signaling inhibitor, can potentially inhibit UNQ6126 by disrupting the Wnt pathway. Inhibition of Wnt signaling may lead to downstream effects that negatively impact UNQ6126 activation and functionality. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2, a Src family kinase inhibitor, can potentially inhibit UNQ6126 by disrupting Src-dependent signaling pathways. This interference may lead to downstream effects that negatively impact UNQ6126 activation and function. | ||||||